Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Expected to Rise, Citigroup Analyst Says

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target increased by Citigroup from $37.00 to $45.00 in a research note released on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

Several other equities analysts have also commented on the stock. JPMorgan Chase & Co. dropped their price target on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. The Goldman Sachs Group increased their target price on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Stifel Nicolaus boosted their price target on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research report on Monday, October 14th. StockNews.com upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Barclays boosted their target price on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $37.64.

Syndax Pharmaceuticals Trading Up 3.1 %

Shares of SNDX opened at $16.09 on Tuesday. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of -4.43 and a beta of 0.92. The firm’s fifty day simple moving average is $18.66 and its 200-day simple moving average is $20.05. Syndax Pharmaceuticals has a twelve month low of $15.00 and a twelve month high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.15. The business had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $9.16 million. During the same period last year, the firm earned ($0.73) earnings per share. On average, analysts predict that Syndax Pharmaceuticals will post -3.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Syndax Pharmaceuticals during the second quarter worth $27,000. Values First Advisors Inc. purchased a new stake in shares of Syndax Pharmaceuticals in the third quarter valued at about $30,000. nVerses Capital LLC acquired a new position in shares of Syndax Pharmaceuticals during the second quarter worth about $33,000. Quantbot Technologies LP purchased a new position in Syndax Pharmaceuticals during the third quarter worth about $49,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after purchasing an additional 541 shares in the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).